Residence, Clinical Features, and Genetic Risk Factors Associated with Symptoms of COVID-19 in a Cohort of Older People in Madrid.


Journal

Gerontology
ISSN: 1423-0003
Titre abrégé: Gerontology
Pays: Switzerland
ID NLM: 7601655

Informations de publication

Date de publication:
2021
Historique:
received: 14 07 2020
accepted: 14 11 2020
pubmed: 12 1 2021
medline: 16 6 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

The older population has been especially affected by the severe acute respiratory syndrome coronavirus 2 pandemic (COVID-19). The aim of the study was to explore the incidence, severity, mortality rate, clinical features, and risk factors of symptoms of COVID-19 in home-dwelling older people, and its association with type of residence, cognitive deterioration, and neurodegenerative diseases. Data about symptoms of COVID-19 were collected through a telephone survey in the cohort of 913 older volunteers of the Vallecas Project, aged 75-90 years, most of them (902) home-dwelling, in Madrid, Spain. The association of demographic and anthropometric measures, genetic polymorphisms, comorbidities, life habits, type of residence, and frailty surrogates were explored as potential risk factors for the incidence, severity, and mortality of COVID-19 in the older population. Sixty-two cases reported symptoms compatible with COVID-19; 6 of them had died, 4 in their home and 2 in the nursing home. Moderate/severe cases were significantly older and more frequently males. The APOE ε4 allele was associated with the presence of symptoms of COVID-19. Higher systolic blood pressure, more intense smoking habit, more alcohol intake, lower consumption of coffee and tea, and cognitive impairment were associated with disease severity. The estimated incidence of symptomatic COVID-19 in this older cohort of Madrid was 6.8%, with an overall mortality rate of 0.7% (18.2% in those living in a nursing home) and a fatality rate of 9.9%. Our exploratory study indicates that life habits, other clinical conditions and, the ε4 variant of the APOE gene are associated with the presence and clinical severity of coronavirus infection.

Sections du résumé

BACKGROUND
The older population has been especially affected by the severe acute respiratory syndrome coronavirus 2 pandemic (COVID-19).
OBJECTIVE
The aim of the study was to explore the incidence, severity, mortality rate, clinical features, and risk factors of symptoms of COVID-19 in home-dwelling older people, and its association with type of residence, cognitive deterioration, and neurodegenerative diseases.
METHODS
Data about symptoms of COVID-19 were collected through a telephone survey in the cohort of 913 older volunteers of the Vallecas Project, aged 75-90 years, most of them (902) home-dwelling, in Madrid, Spain. The association of demographic and anthropometric measures, genetic polymorphisms, comorbidities, life habits, type of residence, and frailty surrogates were explored as potential risk factors for the incidence, severity, and mortality of COVID-19 in the older population.
FINDINGS
Sixty-two cases reported symptoms compatible with COVID-19; 6 of them had died, 4 in their home and 2 in the nursing home. Moderate/severe cases were significantly older and more frequently males. The APOE ε4 allele was associated with the presence of symptoms of COVID-19. Higher systolic blood pressure, more intense smoking habit, more alcohol intake, lower consumption of coffee and tea, and cognitive impairment were associated with disease severity.
CONCLUSIONS
The estimated incidence of symptomatic COVID-19 in this older cohort of Madrid was 6.8%, with an overall mortality rate of 0.7% (18.2% in those living in a nursing home) and a fatality rate of 9.9%. Our exploratory study indicates that life habits, other clinical conditions and, the ε4 variant of the APOE gene are associated with the presence and clinical severity of coronavirus infection.

Identifiants

pubmed: 33429394
pii: 000513182
doi: 10.1159/000513182
pmc: PMC7900450
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-289

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Teodoro Del Ser (T)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Miguel A Fernández-Blázquez (MA)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Meritxell Valentí (M)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

María Ascensión Zea-Sevilla (MA)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Belén Frades (B)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Eva Alfayate (E)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Laura Saiz (L)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Olga Calero (O)

Centro de Investigación Biomédica en Red sobre Enfermedades Degenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Chronic Disease Program, Institute of Health Carlos III, Madrid, Spain.

Fernando José García-López (FJ)

National Epidemiology Centre, Institute of Health Carlos III, Madrid, Spain.

Alberto Rábano (A)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.

Miguel Medina (M)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Degenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Miguel Calero (M)

Alzheimer's Disease Investigation Research Unit, CIEN Foundation, Institute of Health Carlos III, Queen Sofia Foundation Alzheimer Research Center, Madrid, Spain, mcalero@fundacioncien.es.
Centro de Investigación Biomédica en Red sobre Enfermedades Degenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, mcalero@fundacioncien.es.
Chronic Disease Program, Institute of Health Carlos III, Madrid, Spain, mcalero@fundacioncien.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH